Skip to main content
GHRS
NASDAQ Life Sciences

GH Research的GH001疗效不受之前治疗失败次数影响，新数据显示

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$13.96
Mkt Cap
$865.93M
52W Low
$7.98
52W High
$19.51
Market data snapshot near publication time

summarizeSummary

GH Research宣布了一项关于其二期临床试验数据的新分析，用于治疗抗抑郁药物无效的抑郁症（TRD）患者的mebufotenin（GH001），证明该药物的疗效与之前的抗抑郁药物治疗失败次数无关。这一发现与TRD中随着之前治疗失败次数增加而典型的缓解率下降形成对比，发表在Psychopharmacology Bulletin上，伴随着在JAMA Psychiatry上发表的一期临床试验结果。这一新见解加强了GH001的特征，表明即使对于有广泛治疗史的患者，也能带来持续的益处。这可能会扩大该药物的潜在市场，并在其推进全球关键试验的过程中提高其竞争地位。

在该公告发布时，GHRS的交易价格为$13.96，交易所为NASDAQ，所属行业为Life Sciences，市值约为$8.7亿。 52周交易区间为$7.98至$19.51。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed GHRS - Latest Insights

GHRS
Apr 29, 2026, 8:26 AM EDT
Filing Type: 424B5
Importance Score:
8
GH Research Prices $117.5M Public Offering at $18.00 Per Share to Fund Clinical Development
Sentiment: Neutral
View Wiseek Article
GHRS
Apr 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
$117.5M Underwritten Offering Priced at $18.00 Per Share, Below Current Market
Sentiment: Negative
View Wiseek Article
GHRS
Apr 20, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
White House Executive Order to Accelerate Psychedelic Mental Health Treatments, Bolstering GH Research
Sentiment: Positive
View Wiseek Article
GHRS
Mar 25, 2026, 11:10 AM EDT
Source: GlobeNewswire
Importance Score:
7
GH Research's GH001 Efficacy Holds Strong Regardless of Prior Treatment Failures, New Data Shows
Sentiment: Positive
View Wiseek Article
GHRS
Mar 05, 2026, 7:08 AM EST
Source: Dow Jones Newswires
Importance Score:
8
GH Research's 2025 Loss Per Share Widens to 79 Cents
Sentiment: Negative
View Wiseek Article
GHRS
Mar 05, 2026, 7:04 AM EST
Filing Type: 6-K
Importance Score:
7
GH Research Reports Full Year 2025 Results, Strong Cash Position, and Targets 2026 Phase 3 Initiation for GH001
Sentiment: Neutral
View Wiseek Article
GHRS
Jan 15, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
9
GH Research Reports Strong Phase 2b/2a Data for GH001 in Treatment-Resistant Depression, Postpartum Depression, and Bipolar II
Sentiment: Positive
View Wiseek Article
GHRS
Jan 13, 2026, 7:15 AM EST
Filing Type: 6-K
Importance Score:
9
GH Research's GH001 Shows Significant Efficacy and Tolerability in Phase 2b TRD Trial
Sentiment: Positive
View Wiseek Article
GHRS
Jan 08, 2026, 7:30 AM EST
Filing Type: 6-K
Importance Score:
8
GH Research Reports Positive Phase 2b TRD and Phase 2a Bipolar II Depression Trial Results for GH001
Sentiment: Positive
View Wiseek Article
GHRS
Jan 05, 2026, 7:20 AM EST
Filing Type: 6-K
Importance Score:
9
FDA Lifts Clinical Hold on GH001, Paving Way for Global Phase 3 in Treatment-Resistant Depression
Sentiment: Positive
View Wiseek Article